BOSTON Program

Breath Therapeutics' lead program, BOSTON, develops the first therapy for the treatment of Bronchiolitis Obliterans, which is a severe respiratory complication after lung transplantation with fatal outcome.

Based on new and promising clinical results from Aldo Iacono and his lung transplantation team at the University of Maryland, USA, we are currently preparing to initiate two robust Phase 3 clinical trials in the US and Europe.

Breath Therapeutics has received orphan drug designation for "Treatment of Bronchiolitis Obliterans" in the US and Europe.